REPL 241220 17.50C (REPL241220C17500) Stock Options, News & Quotes

US OptionsDetailed Quotes

REPL241220C17500

Watchlist

0.05
-0.20-80.00%

15min DelayClose Dec 3 16:00 ET

0.05High0.05Low

Intraday

5D
Daily

News

Replimune Price Target Raised to $19 From $16 at Jefferies
TipRanks16:06 ET
Express News | Replimune Shares Extend Gains; Last up 8%
ReutersNov 26 09:54 ET
Express News | Replimune Group Inc - Amendment Reduces Atm Offering to $89 Mln
ReutersNov 26 08:33 ET
Express News | Replimune Group Inc - Co & Leerink Partners LLC Enters Amendment No. 2 to Sales Agreement
ReutersNov 26 08:33 ET
Reported Earlier, Replimune Prices $140M Upsized Public Offering Of 6,923,000 Common Shares At $13/Share
BenzingaNov 26 01:59 ET
Replimune Expects Gross Proceeds From Offering to Be Approximately $140M>REPL
Dow JonesNov 26 00:01 ET

Comments

Kevin Travers

Nov 22 15:03

Columns Friday Market Climbs | Wall Street Today

The market climbed Friday after a week of waiting and reacting to Nvidia earnings and Bitcoin's all-time highs.
The market overall advanced Friday. Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded +0.35%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 0.97%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.16%.
MACRO
In macroeconomics, S&P Global released its composite and service PMI. Composite came in at a two-year high, 55.3...

Weekly Buzz

Kevin Travers

Nov 22 10:06

Columns Market Climbs, Bitcoin Close to $100k | Live Stock

Good morning, traders. Happy Friday, November 22nd. Without the news and animal spirits moving markets, you will not make it through today. My name is Kevin Travers, and the S&P 500 and market climbed this morning, here is what's moving:
$Super Micro Computer (SMCI.US)$ climbed 15%, after earlier this week, the firm said it submitted a plan to release its six-month delayed 10k with a new auditor, BDO USA, and filed for a time extension to file it...

Bitcoin ups and downs: How far is it from $100,000?

Jaguar8

Nov 22 08:40

😍😍😍

$Replimune (REPL.US)$

Jaguar8

Nov 21 22:29

On watchlist. Reason: Breakthrough Therapy Designation + Biologics License Application in Accelerated pathway for Melanoma. News after hours

$Replimune (REPL.US)$

Trytosaveabit

Nov 21 15:09

News

$Replimune (REPL.US)$ Reuters· 3 mins ago
Replimune Receives Breakthrough Therapy Designation for Rp1 and Submits Rp1 Biologics License Application to the FDA Under the Accelerated Approval Pathway